MK-677 (Ibutamoren) news and clinical trials

A narrative review of 76 studies on peptide use in urology and sexual medicine found that while some agents like Bremelanotide and Tesamorelin have clinical backing, many others like CJC-1295 remain unvalidated and accessible only through unregulated markets.

A scoping review concluded that claims regarding peptide supplements for musculoskeletal recovery remain unsubstantiated by current human trials. Authors warned of potential risks including cardiovascular complications.

Lumos Pharma registered a phase 2 trial to evaluate the efficacy and safety of LUM-201 as an adjunct to oral semaglutide in 202 obese adults between the ages of 60 and 85 years. The study is not yet recruiting.

Researchers found that moderate doses of the ghrelin receptor agonist ibutamoren increased cost sensitivity in rats during conflict-based decision-making. This effect was linked to increased neuronal activity in dorsomedial striosomes.

Researchers reported a fast analytical workflow to detect 54 prohibited doping compounds in dried blood spots, serum, and plasma using liquid chromatography and mass spectrometry. The study found that storing samples in dried matrices allows for non-refrigerated transport, reducing costs.

Lumos Pharma completed a phase 2 trial of daily oral LUM-201 in 104 prepubertal children with idiopathic growth hormone deficiency. The study investigated LUM-201 as a treatment and assessed a predictive enrichment marker strategy to select likely responders.

Doctors reported a case of a 54-year-old male who required a splenectomy for atraumatic splenic rupture after using MK-677 and RAD-140. The study authors suggest the use of performance-enhancing compounds may have been a contributing factor in the context of a vascular malformation.

Lumos Pharma completed a phase 2 study evaluating the growth and safety of LUM-201 in 15 children with idiopathic growth hormone deficiency who had previously received 12 months of rhGH treatment.

Massachusetts General Hospital completed a pilot phase 2 study of 12 participants to investigate if LUM-201 could decrease intrahepatic lipid accumulation in patients with nonalcoholic fatty liver disease.

Researchers found that acute stress in mice suppressed hunger-driven food seeking via activation of the paraventricular hypothalamic nucleus. Administration of the ghrelin receptor agonist MK-677 reversed this suppression by inhibiting specific neurons in that region.